BBHC
VNRX icon

Brown Brothers Harriman & Co’s VolitionRx Ltd VNRX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio VNRX Stock Details VNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-191
Closed -$11K – 1129
2017
Q4 		$11K Buy
+191
New +$11.2K ﹤0.01% 747

Other funds holding VNRX

LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brown Brothers Harriman & Co's VNRX Position: Q1 2018 in Review

Brown Brothers Harriman & Co sold out of VolitionRx Ltd (VNRX) in Q1 2018, closing a stake of 191 shares — an estimated $11K sold.

Brown Brothers Harriman & Co first reported a position in VNRX in Q4 2017 and held it in 1 quarter. The position peaked at $11K in Q4 2017. 25 funds tracked by Wall St. Rank hold VNRX as of Q1 2018.

  • Brown Brothers Harriman & Co reported no remaining VolitionRx Ltd position as of Q1 2018 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 191 VolitionRx Ltd shares in Q1 2018, an estimated $11K.
  • Brown Brothers Harriman & Co first reported a position in VolitionRx Ltd in Q4 2017 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's VolitionRx Ltd position peaked at $11K in Q4 2017.
  • 25 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q1 2018.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2018, filed 14 May 2018.